- Home
- PHAR vs UAN Comparison
PHAR vs UAN Comparison
Compare PHAR & UAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- UAN
- Stock Information
- Founded
- PHAR 1988
- UAN 2007
- Country
- PHAR Netherlands
- UAN United States
- Employees
- PHAR N/A
- UAN N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- UAN Agricultural Chemicals
- Sector
- PHAR Health Care
- UAN Industrials
- Exchange
- PHAR Nasdaq
- UAN Nasdaq
- Market Cap
- PHAR 718.1M
- UAN 773.6M
- IPO Year
- PHAR N/A
- UAN 2011
- Fundamental
- Price
- PHAR $10.45
- UAN $89.81
- Analyst Decision
- PHAR Strong Buy
- UAN
- Analyst Count
- PHAR 3
- UAN 0
- Target Price
- PHAR $30.00
- UAN N/A
- AVG Volume (30 Days)
- PHAR 2.6K
- UAN 21.1K
- Earning Date
- PHAR 07-31-2025
- UAN 07-28-2025
- Dividend Yield
- PHAR N/A
- UAN 7.89%
- EPS Growth
- PHAR N/A
- UAN N/A
- EPS
- PHAR N/A
- UAN 7.13
- Revenue
- PHAR $320,708,000.00
- UAN $540,525,000.00
- Revenue This Year
- PHAR $13.31
- UAN N/A
- Revenue Next Year
- PHAR $7.68
- UAN N/A
- P/E Ratio
- PHAR N/A
- UAN $12.50
- Revenue Growth
- PHAR 24.13
- UAN N/A
- 52 Week Low
- PHAR $6.65
- UAN $62.94
- 52 Week High
- PHAR $12.61
- UAN $90.49
- Technical
- Relative Strength Index (RSI)
- PHAR 47.51
- UAN 81.92
- Support Level
- PHAR $10.41
- UAN $81.18
- Resistance Level
- PHAR $11.50
- UAN $90.49
- Average True Range (ATR)
- PHAR 0.32
- UAN 1.62
- MACD
- PHAR -0.17
- UAN 0.65
- Stochastic Oscillator
- PHAR 2.26
- UAN 92.64
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.